Immunovant, Inc.
IMVT · XNASCIK 1764013fmd_13WARN6PRDAVGTBSYQSH0QRD95Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Apr 01, 2018 to Sep 30, 2026, 34 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Net interest income | – | – | – | 0 | 8 | 25 | – | – |
| Research and development | 26 | 48 | 69 | 102 | 160 | 213 | 361 | 457 |
| Total operating expenses | 28 | 66 | 108 | 156 | 218 | 283 | 438 | 533 |
| Interest expense | – | 1 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | (0) | 0 | 0 | (1) | (0) | (1) | 0 | 2 |
| Income before taxes | (29) | (66) | (108) | (157) | (211) | (259) | (413) | (505) |
| Income tax expense | 0 | 0 | (0) | (0) | 0 | 1 | 1 | 0 |
| Net income from continuing operations | (29) | (66) | (107) | (157) | (211) | (259) | (414) | (506) |
| Net income | (29) | (66) | (107) | (157) | (211) | (259) | (414) | (506) |